ResMed Inc (RMD) carries a ŷRobot AI score of 62 out of 100. The model's fair value estimate is $239.30, 7.4% above the last close of $222.84. The chart signal reads Sell.
| Metric | RMD |
|---|---|
| AI score | 62 / 100 |
| Chart signal | Sell |
| Fair value estimate | $239.30 |
| Upside to fair value | 7.4% |
| Previous close | $222.84 |
| P/E | 22.63 |
| Price / sales | 6.13 |
| Market cap | $32.02B |
| EPS | 10.62 |
| Revenue growth | 11.7% |
| 1-year price change | 0.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
As of Sep 29, 2026, ŷRobot's fair-value model estimates ResMed Inc (RMD) at $239.30 against a last close of $222.84, implying 7.4% upside to the model's estimate.
The chart-signal model classifies RMD as Neutral as of Sep 29, 2026, with a signal score of -0.11 on a -1 to 1 scale.
RMD scores 62 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Sep 29, 2026.
RMD trades at 22.6 times earnings and 6.1 times sales as of Sep 29, 2026.
ŷRobot's seasonal forecast curve for RMD reads -0.8% at 30 days, +1.4% at 90 days, and +0.5% at one year as of Sep 29, 2026. Seasonal tendencies are historical patterns, not predictions.
ResMed Inc's revenue growth is +11.7% and free-cash-flow growth is -37.0% on the latest reported figures.
RMD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.